ATX-MS-1467 in Patients With Relapsing Forms of Multiple Sclerosis

• MRI scans [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]
  General MRI evaluation of brain lesions for numbers of gadolinium enhancing lesions during the study.
• Injection site reactions [ Time Frame: 20 weeks ] [ Designated as safety issue: Yes ]
  Injection site reactions as reported by the subjects in the diary card.
• Immunology [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]
  Proliferation responses to myelin basic protein and cytokine release

Phase 1 study to assess the safety and biological activity of ATX-MS-1467 in patients with relapsing forms of multiple sclerosis. This will be an open label upward dose titration involving injections on 9 occasions, each two weeks apart. After dosing is complete there will be a 22 week follow up period. Blood samples will be drawn throughout the study to monitor safety and the body's response to the injections and MRI scans will be performed on several occasions to follow the course of the multiple sclerosis during the trial.

• Experimental: Intradermal injection
  Injections will be given by the intradermal route
  Intervention: Biological: ATX-MS-1467
• Experimental: Subcutaneous injection
  Injections will be given by the subcutaneous route
  Intervention: Biological: ATX-MS-1467

Inclusion Criteria:

• 1. Patients who have definite relapsing multiple sclerosis disease as defined by the McDonald criteria (McDonald et al., 2001 and 2005) and as assessed by a neurologist.

  2. HLA DRB1*15 positive.

  3. High baseline levels of T-cell proliferation in response to myelin basic protein, defined as >1000 cpm with a >3 stimulation index compared to background.

  4. Disease duration equal to or less than 10 years (from the first clinical event).

  5. At least one documented relapse in the previous 12 months or two relapses within the previous 24 months prior to screening.

  6. Must be in a clinically stable or improving neurological state during the 28 days preceding Screening.

  7. EDSS score < 5.5.

Exclusion Criteria:

• 1. Subjects treated with β-interferon, plasma exchange, intravenous gamma globulin within the 3 months prior to Study Day 1 2. Subjects treated with glatiramer acetate at any time in the past 3. Subjects who have been treated with parenteral steroids or adrenocorticotropic hormone within 3 months days prior to Study Day 1 4. Prior treatment with: cytotoxic agents (including but not limited to cladribine, mitoxantrone, cyclophosphamide, azathioprine, methotrexate), fingolimod, laquinimod, teriflunomide, total lymphoid irradiation, stem cell or bone marrow transplantation, or monoclonal antibody therapy (including natalizumab, daclizumab, alemtuzumab) 5. Prior use of disease related T-cell vaccine or peptide-tolerising agent to treat MS 6. Use of any investigational drug or experimental procedure within 6 months prior to Study Day 1 including cytokine or anti-cytokine therapy

• Aptiv Solutions (UK)
• ClinStar Europe LLC (Russia)